“we expect this to be a much more stable market. We plan to retain that kind of leadership share, and we expect volumes to be more stable here.”

In context

“t that we will continue to maintain meaningful market share. A lot of that has to do with our commercial execution, as well as the fact that many accounts, particularly nonretail accounts, prefer to stock a single vaccine. So we'll see that evolve over the course of the year. And while we don't think that there's much catch-up opportunity in the 65-plus, we also think there is growth opportunity in the 50 to 64 age group that brings about 30 million adults into the eligible population. So those will be the dynamics in adult. Now in [indiscernible] there again, we have very significant market share. And on the theme of improved market share across all of our vaccines, we saw a 12 percentage point improvement from August to August '23 to December '24 in our pediatric market share. And here, we expect this to be a much more stable market. We plan to retain that kind of leadership share, and we expect volumes to be more stable here. Albert Bourla: Okay, thank you very much. Next question. Operator: We'll go next to Dave Risinger with Leerink Partners. Please go ahead. David Risinger: Yes, thanks for introduction. Thanks for all the update. Yes. So my question is just going back to RFK Jr. So assuming he is confirmed as HHS Secretary, and given his history of suing manufacturers and his commentary on lawsuits in the hearings last week, could you just help us understand his ability as HHS Secretary to remove U.S. vaccine liability protections that manufacturers currently benefit from and allow manufacturers the freedom to develop and sell vaccines that save lives? Thank you. Albert Bourla: Yes. Look, I don't want to comment because these are legal issues, but I believe that the liability is through Senate -- through Co”